

# BONE DECALCIFICATION PROCEDURE FOR ONCOTYPE MAP™ PAN-CANCER TISSUE TEST

The Oncotype MAP™ Pan-Cancer Tissue test relies on a formalin-fixed paraffin-embedded (FFPE) tissue block or slides for performance of next-generation sequencing (NGS) as well as immunohistochemical (IHC) staining.

Stronger bone fixation acids, like hydrochloric or even formic acid, can destroy the DNA and negatively impact NGS. Studies performed to assess the impact of decalcification have shown that EDTA-based decalcification has the least impact on DNA integrity; thus, use of EDTA is highly encouraged.<sup>1,2</sup>

EDTA allows for a gentle decalcification process in reaching an optimal pH of between 7.0 and 7.4.

## How to Prepare a Bone Sample for Oncotype MAP Submission:

- 1 Establish your preferred EDTA solution of  $\leq 14\%$ . OSTEOSOFT® (10 - <20% pH range) and Versenate ( $\leq 10\%$  pH range) are both acceptable options. **Optimal decalcification pH is 7.0 - 7.4.**
- 2 Completely fix specimen prior to decalcification.
- 3 Follow manufacturer's instructions for specimen preparation and use of EDTA solution. **Decalcification time and quantity of solution used is dependent upon the size, type and density of the respective tissue.**
- 4 Monitor for decalcification end point. Decalcified tissue should be rubberlike in consistency and exhibit weak resistance to probing.
- 5 Process and embed specimen using standard practice guidelines.
- 6 Refer to the Oncotype MAP Pan-Cancer Tissue Specimen Submission Guidelines for complete information on FFPE sample submission, specimen rejection criteria, testing priority and shipping.

QUESTIONS? CONTACT CUSTOMER SERVICE AT  
1-866-662-6897 or [oncotypemap@exactsciences.com](mailto:oncotypemap@exactsciences.com)

### References:

1. Schrijver, WA, et al. Influence of decalcification procedures on immunohistochemistry and molecular pathology in breast cancer. *Mod Pathol*, 2016. 29(12):1460-1470
2. Sourced from: <https://www.captodayonline.com/qa-column-417/>

Osteosoft® is a registered trademark of Merck KGaA

Oncotype MAP and Oncotype MAP Pan-Cancer Tissue Test are trademarks of Genomic Health, Inc. Exact Sciences is a registered trademark of Exact Sciences Corporation. ©2021 Genomic Health, Inc. All rights reserved. EXS50105\_0121

## About Exact Sciences

A leading provider of cancer screening and diagnostic tests, Exact Sciences helps people get the answers they need to make more informed decisions across the cancer continuum. Building on the success of the Cologuard™ and Oncotype DX™ tests, Exact Sciences is investing in its product pipeline to take on some of the deadliest cancers and improve patient care. Through an innovative, rigorous approach, and with the support of visionary collaborators, we're helping advance the fight against cancer.

**oncotype MAP™**  
*Pan-Cancer Tissue*

Paradigm Diagnostics, Inc., a wholly-owned subsidiary of Exact Sciences Corp.  
445 N. 5th Street, Suite 300 | Phoenix, AZ 85004 | 866.662.6897 | [exactsciences.com](http://exactsciences.com)

**EXACT  
SCIENCES**